Aspirin also slowed the rise in fasting blood glucose over time, but its risks are still believed to outweigh its benefits, unless the individual has already had a first cardiac event.
New ESC guidelines recommend using both an SGLT2 inhibitor and a GLP-1 receptor agonist simultaneously to treat people with type 2 diabetes and established cardiovascular disease.
In STEP-HFpEF, a prospective, randomized study of adults with HFpEF and obesity, weekly semaglutide weight-loss injections for 1 year led to substantial improvements in physical function and symptoms.
Long-term results still show higher mortality among patients with schizophrenia vs the general population. Substance use is a main predictor of mortality, and suicide accounted for 27.5% of all deaths.